BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 19396409)

  • 1. Effect of trimetazidine on quality of life in elderly patients with ischemic dilated cardiomyopathy.
    Marazzi G; Gebara O; Vitale C; Caminiti G; Wajngarten M; Volterrani M; Ramires JA; Rosano G; Fini M
    Adv Ther; 2009 Apr; 26(4):455-61. PubMed ID: 19396409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease.
    Vitale C; Wajngaten M; Sposato B; Gebara O; Rossini P; Fini M; Volterrani M; Rosano GM
    Eur Heart J; 2004 Oct; 25(20):1814-21. PubMed ID: 15474696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d'Abruzzo Trimetazidine Trial.
    Di Napoli P; Di Giovanni P; Gaeta MA; Taccardi AA; Barsotti A
    J Cardiovasc Pharmacol; 2007 Nov; 50(5):585-9. PubMed ID: 18030070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trimetazidine potentiates the effects of exercise training in patients with ischemic cardiomyopathy referred for cardiac rehabilitation.
    Belardinelli R; Lacalaprice F; Faccenda E; Volpe L
    Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):533-40. PubMed ID: 18797405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trimetazidine and the contractile response of dysfunctional myocardium in ischaemic cardiomyopathy.
    Belardinelli R
    Rev Port Cardiol; 2000 Nov; 19 Suppl 5():V35-9. PubMed ID: 11206102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of free fatty acid inhibition on silent and symptomatic myocardial ischemia in diabetic patients with coronary artery disease.
    Marazzi G; Wajngarten M; Vitale C; Patrizi R; Pelliccia F; Gebara O; Pierri H; Ramires JA; Volterrani M; Fini M; Rosano GM
    Int J Cardiol; 2007 Aug; 120(1):79-84. PubMed ID: 17134770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study.
    Rosano GM; Vitale C; Sposato B; Mercuro G; Fini M
    Cardiovasc Diabetol; 2003 Nov; 2():16. PubMed ID: 14641923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy.
    Belardinelli R; Cianci G; Gigli M; Mazzanti M; Lacalaprice F
    J Cardiovasc Pharmacol; 2008 Jun; 51(6):611-5. PubMed ID: 18574390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy.
    Fragasso G; Piatti Md PM; Monti L; Palloshi A; Setola E; Puccetti P; Calori G; Lopaschuk GD; Margonato A
    Am Heart J; 2003 Nov; 146(5):E18. PubMed ID: 14597947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of trimetazidine added to maximal anti-ischemic therapy in patients with advanced coronary artery disease.
    Grabczewska Z; Białoszyński T; Szymański P; Sukiennik A; Swiatkiewicz I; Koziński M; Kochman W; Grześk G; Kubica J
    Cardiol J; 2008; 15(4):344-50. PubMed ID: 18698543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure.
    Fragasso G; Palloshi A; Puccetti P; Silipigni C; Rossodivita A; Pala M; Calori G; Alfieri O; Margonato A
    J Am Coll Cardiol; 2006 Sep; 48(5):992-8. PubMed ID: 16949492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of trimetazidine with atenolol in patients with syndrome X: effects on diastolic function and exercise tolerance.
    Leonardo F; Fragasso G; Rossetti E; Dabrowski P; Pagnotta P; Rosano GM; Chierchia SL
    Cardiologia; 1999 Dec; 44(12):1065-9. PubMed ID: 10687257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial effects of trimetazidine treatment on exercise tolerance and B-type natriuretic peptide and troponin T plasma levels in patients with stable ischemic cardiomyopathy.
    Di Napoli P; Di Giovanni P; Gaeta MA; D'Apolito G; Barsotti A
    Am Heart J; 2007 Sep; 154(3):602.e1-5. PubMed ID: 17719313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The effects of trimetazidine on left ventricular function and physical exercise tolerance in patients with ischemic cardiomyopathy].
    Sisakian AS; Torgomian AL; Barkhudarian AL
    Klin Med (Mosk); 2006; 84(10):55-8. PubMed ID: 17201276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of trimetazidine plus sildenafil to chronic nitrates in the control of myocardial ischemia during sexual activity in patients with coronary artery disease.
    Rosano GM; Marazzi G; Patrizi R; Cerquetani E; Vitale C; Volterrani M; Fini M; Mercuro G
    Am J Cardiol; 2005 Feb; 95(3):327-31. PubMed ID: 15670539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapeutic value of trimetazidine in patients with coronary heart disease and left ventricular dysfunction].
    Multicentral Collaborative Group on Trimetazidine (Phase IV)
    Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Sep; 33(9):793-5. PubMed ID: 16266453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure.
    Fragasso G; Perseghin G; De Cobelli F; Esposito A; Palloshi A; Lattuada G; Scifo P; Calori G; Del Maschio A; Margonato A
    Eur Heart J; 2006 Apr; 27(8):942-8. PubMed ID: 16510466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical benefits of a metabolic approach in the management of coronary patients.
    Marzilli M
    Rev Port Cardiol; 2000 Nov; 19 Suppl 5():V25-30. PubMed ID: 11206100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical efficacy of combined therapy with enalapril + trimetazidine in patients with hypertension comorbid with ischemic heart disease and metabolic disturbances].
    Petelina TI; Gapon LI; Bakhmatova IuA; Zhevagina IA
    Ter Arkh; 2005; 77(8):19-23. PubMed ID: 16206600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical and hemodynamic efficacy of selective beta-blocker bisoprolol and cytoprotector trimetazidine in the treatment of chronic cardiac failure in patients with ischemic heart disease].
    Fedorova TA; Il'ina IuV; Sotnikova TI; Rybakova MK; Loshchits NV
    Ter Arkh; 2004; 76(3):62-8. PubMed ID: 15108463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.